| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.4 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.4 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |